SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Conroy Kevin T | Director | 2026-05-20 | Option exercise | 1745 | $0 |
| Dallas Kevin J | Director | 2026-05-20 | Option exercise | 1745 | $0 |
| LACOB JOSEPH | Director | 2026-05-20 | Option exercise | 1745 | $0 |
| LARKIN C RAYMOND JR | Director | 2026-05-20 | Option exercise | 2326 | $0 |
| MORROW GEORGE J | Director | 2026-05-20 | Option exercise | 1745 | $0 |
| Myong Anne | Director | 2026-05-20 | Option exercise | 1745 | $0 |
| Poul Mojdeh | Director | 2026-05-20 | Option exercise | 1745 | $0 |
| SIEGEL SUSAN E | Director | 2026-05-20 | Option exercise | 1745 | $0 |
| Saia Andrea Lynn | Director | 2026-05-20 | Option exercise | 1745 | $0 |
| Vitalone Britt J. | Director | 2026-05-20 | Option exercise | 1443 | $0 |
| Coletti Julie Ann | EVP, CHIEF LEGAL & REGULATORY | 2026-02-20 | Option exercise | 5864 | $0 |
| Coletti Julie Ann | EVP, CHIEF LEGAL & REGULATORY | 2026-02-20 | Tax withholding | 1718 | $326K |
| HOGAN JOSEPH M | President and CEO, Director | 2026-02-20 | Option exercise | 40248 | $0 |
| HOGAN JOSEPH M | President and CEO, Director | 2026-02-20 | Tax withholding | 16107 | $3.1M |
| Hockridge Stuart A | EVP, GLOBAL HR | 2026-02-20 | Option exercise | 4310 | $0 |
| Hockridge Stuart A | EVP, GLOBAL HR | 2026-02-20 | Tax withholding | 1210 | $230K |
| Morici John | EVP, CHIEF FINANCIAL OFFICER | 2026-02-20 | Option exercise | 7848 | $0 |
| Morici John | EVP, CHIEF FINANCIAL OFFICER | 2026-02-20 | Tax withholding | 2549 | $484K |
| Morici John | EVP, CHIEF FINANCIAL OFFICER | 2026-02-18 | Open-market sell | 7969 | $1.5M |
| HOGAN JOSEPH M | PRESIDENT AND CEO, Director | 2025-08-01 | Open-market buy | 7576 | $996K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Risk exposure broadened materially across six distinct themes, with no offsetting easings — the most consequential additions are expanded AI liability, new geopolitical/trade risks (Section 232, tariffs, Mexico security, Hamas conflict), and escalating EU antitrust enforcement constraints. Talent retention pressure is compounded by a simultaneous restructuring and mandatory return-to-office mandate. While no single change rises to existential/solvency level, the pervasive, multi-front nature of the worsening pushes intensity to moderate.
4 company-specific · 4 common-mode
New disclosure of material customer concentration and pricing pressure risk. DSOs/OSOs are increasingly important channel; their reduced purchasing or negotiating leverage could materially impact adoption, ASPs, margins, and profitability.
Our results of operations may be adversely affected if doctors at DSOs, orthodontic service organizations (“OSOs”) or other large group practices reduce, delay, or do not increase their…
New disclosure of recent restructuring (Q3 2025) and mandatory five-day office return policy, both escalating talent retention risks and attrition concerns.
If we cannot attract, motivate, train or retain personnel, it will be difficult to achieve our strategic priorities, which could materially adversely affect our business, financial condition and…
New specific risks added: Section 232 investigation on medical devices, Mexico gang/drug trafficking threats, Hamas conflict escalation, and explicit acknowledgment that contingency measures may be insufficient.
Geopolitical events, tariffs and trade policies, and military conflicts have and could in the future materially affect our business, financial condition and results of operations . Geopolitical…
Added specific disclosure of heightened EU antitrust scrutiny on settlements and explicit risk that settlement terms may be constrained, escalating enforcement complexity.
Legal, Regulatory and Compliance Risks We are subject to antitrust and competition regulations, litigation and enforcement that may result in fines, penalties, restrictions on our business practices…
Substantially expanded AI risk disclosure. Added third-party model IP infringement liability, confidential data loss in AI systems, and unintended AI output risks. Escalates legal and operational exposure.
AI and machine learning technologies in our products, services and IT systems may result in legal and regulatory risks, reputational harm or have other adverse consequences to our business. We have…
New disclosure of tariff risk as operational factor. Adds material geopolitical/trade exposure not previously mentioned.
Operational Risks Our quarterly and annual results of operations have and will continue to fluctuate in the future, and we may not accurately predict the timing and amount of customer demand and our…
Added SEC climate disclosure obligations and CSRD specificity; expanded conflict minerals discussion removed; added microplastics restrictions; heightened regulatory scrutiny language.
Current and anticipated sustainability and social (“Sustainability”) laws and scrutiny of our Sustainability policies and practices may materially increase our costs, expose us to liability, and…
Added reference to "One Big Beautiful Bill Act" and new disclosure of aggressive tax interpretations by jurisdictions and international trade volatility risks.
New tax laws and practices, changes to existing tax laws and practices, or disputes regarding the positions we take regarding tax laws, could negatively affect our provision for income taxes as well…
The filing discloses the appointment of Quentin Blackford, an experienced healthcare executive (currently CEO of iRhythm Technologies), to Align Technology's Board of Directors effective August 27, 2026. While the section also mentions Andrea L. Saia's resignation, the principal disclosed action centers on the appointment of a new director. Blackford's appointment is material as it represents a change in board composition and governance at a large-cap medical device company, and his background in healthcare and digital innovation is relevant to investor assessment of board quality and strategic direction.
View raw filing on EDGAR →Align Technology issued a press release on July 29, 2026 disclosing its second quarter 2026 financial results, including record revenues of $1.06 billion (up 4.3% year-over-year), record Clear Aligner shipments of 691.8 thousand cases (up 7.4% year-over-year), and diluted EPS of $1.51 GAAP and $2.64 non-GAAP. The filing explicitly states this is an earnings release for Q2'26 results furnished as Exhibit 99.1, which is the standard disclosure mechanism for quarterly financial results under Item 2.02.
View raw filing on EDGAR →The disclosure centers on board refreshment with appointment of three new independent directors, engagement of a strategic consulting firm, and increased share repurchase commitment, all following constructive discussions with Elliott Investment Management. While the appointment of directors could be classified as exec_appointment, the filing emphasizes the broader governance initiative (board refreshment, strategic review, capital allocation) rather than individual director appointments. The material nature stems from the activist investor engagement and comprehensive strategic review, making this a governance event that encompasses multiple governance actions beyond a simple appointment.
View raw filing on EDGAR →Julie Coletti, Executive Vice President and Chief Legal and Regulatory Officer, resigned effective August 1, 2026, to join Illumina as Chief Legal Officer. This is a clear departure of a named executive officer from a senior leadership position responsible for legal and regulatory matters, making it material to investors' assessment of the company's governance and leadership continuity.
View raw filing on EDGAR →Kevin Conroy was appointed as Chairman of the Board effective July 1, 2026, succeeding C. Raymond Larkin, Jr., who retired from the Chairman role but will remain on the Board through December 31, 2026.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Align Technology's 2026 Annual Meeting of Stockholders held on May 20, 2026. The filing presents certified voting tallies for four proposals: election of ten directors, advisory vote on named executive officer compensation, ratification of PricewaterhouseCoopers LLP as auditor, and ratification of a special meeting provision in the bylaws. This is a textbook shareholder_vote_results event under Item 5.07.
View raw filing on EDGAR →